

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61F 2/02	A1	(11) International Publication Number: WO 96/13227 (43) International Publication Date: 9 May 1996 (09.05.96)
(21) International Application Number: PCT/US95/13443 (22) International Filing Date: 20 October 1995 (20.10.95) (30) Priority Data: 08/327,359 21 October 1994 (21.10.94) US (71) Applicant (for all designated States except US): UNIVERSITY OF MICHIGAN [US/US]; Technology Management Office, Wolverine Towers, Room 2071, 3003 South State Street, Ann Arbor, MI 48109-1280 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): LEVY, Robert, J. [US/US]; 2241 Belmont, Ann Arbor, MI 48104 (US). LERNER, Eyal [IL/IL]; Apartment 26, 2 Ben Eliezer Street, 77402 Ashdod (IL). (74) Agents: ROHM, Benita, J. et al.; Rohm & Monsanto, 512 Springfield Avenue, Cranford, NJ 07016 (US).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: CALCIFICATION-RESISTANT BIOPROSTHETIC TISSUE AND METHODS OF MAKING SAME (57) Abstract Naturally-derived bioprosthetic materials are treated with epoxide crosslinking agents. In some embodiments, the tissue is crosslinked with low molecular weight epoxides in aqueous solutions at high pH levels. In other embodiments, the tissue is crosslinked at physiologic pH levels with epoxide crosslinking agents catalyzed with tertiary or quaternary amines, such as Tris or imidazole. In an advantageous embodiment, bioprosthetic tissue is crosslinked and derivatized with an anticalcification agent, such as a polyphosphonate anticalcification agent, using a polyphosphonate:polyepoxide monoadduct.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

CALCIFICATION-RESISTANT BIOPROSTHETIC TISSUE AND METHODS OF MAKING SAME

BACKGROUND OF THE INVENTION

5 This invention relates generally to materials which are resistant to *in vivo* calcification, and more particularly, to methods of preparing calcification-resistant biomaterials, suitable for implantation in a living being, using epoxide crosslinking agents.

More than 100,000 cardiac valve prostheses are placed in patients each year. Frequently, valve replacement surgery is the only means of treating cardiac valve
10 disease. Currently used replacement valves include mechanical valves which may be composed entirely of a synthetic polymeric material such as polyurethane; bioprosthetic valves derived from bovine pericardium or porcine aortic valves; and aortic homografts.

Use of mechanical valves is frequently complicated by thrombosis and tissue
15 overgrowth leading to valvular failure. Bioprosthetic heart valves have improved thrombogenicity and hemodynamic properties as compared to mechanical valve prostheses. However, calcification is the most frequent cause of the clinical failure of bioprosthetic heart valves fabricated from porcine aortic valves or bovine pericardium. Human aortic homograft implants have also been observed to undergo
20 pathologic calcification involving both the valvular tissue as well as the adjacent aortic wall albeit at a slower rate than the bioprosthetic heart valves. Pathologic calcification leading to valvular failure, in such forms as stenosis and/or regurgitation, necessitates re-implantation. Therefore, the use of bioprosthetic heart valves and homografts has been limited because such tissue is subject to calcification.
25 In fact, pediatric patients have been found to have an accelerated rate of calcification so that the use of bioprosthetic heart valves is contraindicated for this group.

Unfortunately, pathologic calcification also further complicates the use of synthetic vascular grafts and other artificial heart devices, such as ventricular assist systems, because it affects the flexibility of the synthetic polymers used to produce
30 the devices.

The mechanism for pathological calcification of cardiovascular tissue is not fully understood. Generally, the term "pathologic calcification" refers to the undesirable deposition of calcium phosphate mineral salts. Calcification may be due to host factors, implant factors, and extraneous factors, such as mechanical stress.

5 There is some evidence to suggest that deposits of calcium are related to devitalized cells, and in particular, cell membranes, where the calcium pump ($\text{Ca}^{+2}\text{-Mg}^{+2}\text{-ATPase}$) responsible for maintaining low intracellular calcium levels is no longer functioning or is malfunctioning. Calcification has been observed to begin with an accumulation of calcium and phosphorous, present as hydroxyapatite, which
10 develops into nodules which can eventually lead to valvular failure.

The preparation of bioprosthetic tissue prior to implantation typically includes treatment to stabilize it against subsequent *in vivo* enzymatic degradation, typically by crosslinking molecules, particularly collagen, on and in the tissue. Various aldehydes have been used for this purpose, including glyoxal, formaldehyde, and
15 glutaraldehyde. Glutaraldehyde, however, is the agent of choice. In addition to fixing the tissue, glutaraldehyde is a good sterilizing agent and it reduces the antigenicity of the tissue. To date, glutaraldehyde is the only effective crosslinking agent for preparing tissues for implantation that can be used at physiologic pH under aqueous conditions. Unfortunately, glutaraldehyde is now known to promote
20 calcification. There is, thus, a need in the art for a means of crosslinking bioprosthetic tissue without promoting calcification.

Non-aldehyde crosslinking agents have been investigated, such as polyepoxides (*e.g.*, polyglycerol polyglycidyl ethers sold under the trademark Denacol by Nagasi Chemicals, Osaka, Japan), but there have been no conclusive
25 studies demonstrating efficacy of polyepoxide cross-linked tissues *in vivo*.

Research on the inhibition of calcification of bioprosthetic tissue has primarily focussed on tissue pretreatment with either detergents or diphosphonate anticalcification agents. Detergent pretreatment with noncovalently-linked detergents, such as sodium dodecyl sulfate (SDS), and a covalently bound detergent,
30 such as amino oleic acid, have been demonstrated to be efficacious in materials

exposed in circulating blood. However, both detergents and diphosphonates tend to wash out of the implanted bioprosthetic tissue with time due to blood-material interactions. Thus, these treatments merely delay the onset of the inevitable calcification process. Accordingly, there is also a need for a means of providing
5 long-term calcification resistance for bioprosthetic heart valves and other implantable biomaterials or devices which are subject to *in vivo* pathologic calcification.

In addition, detergents disadvantageously affect the tissue, resulting in a diminution of the collagen denaturation temperature, or shrink temperature (T_s), which is an important measure of material strength, durability, and integrity. In
10 some cases, use of detergents results in local toxicity. There is, thus, a need for an effective method of imparting anticalcification properties to bioprosthetic tissues which is not accompanied by the deleterious effects of detergents.

All of the foregoing techniques still result in some degree of pathologic calcification *in vivo* as measured by calcium content of explanted specimens. There
15 is, therefore, a need for a treatment that results in a greater level of calcification inhibition.

Systemic use of anticalcification agents, such as diphosphonates, results in significant side effects on bone, and overall, growth. There is, therefore, a need for site specific therapy for prevention of pathologic calcification which would offer low
20 regional drug levels and minimal side effects.

It is, therefore, an object of this invention to provide biomaterials for implantation in a mammal which have increased resistance to *in vivo* pathologic calcification.

It is another object of this invention to provide biomaterials for implantation
25 in a mammal which have a long-term, or prolonged, resistance to *in vivo* pathologic calcification.

It is also an object of this invention to provide biomaterials for implantation in a mammal which have localized calcification inhibition and, hence, avoid the toxic side effects associated with systemic administration of anticalcification agents.

It is additionally an object of this invention to provide methods of fabricating and/or treating biomaterials for implantation in a mammal using epoxy crosslinking agents to render the biomaterials more resistant to *in vivo* pathologic calcification.

SUMMARY OF THE INVENTION

5 The foregoing and other objects are achieved by this invention which provides, in one aspect thereof, a biomaterial suitable for implantation in the interior of the body of a living being which has irreversibly bound thereto an effective amount of an epoxide crosslinking agent to stabilize the tissue and block calcification sites thereby rendering said biomaterial substrate resistant to *in vivo* pathologic
10 calcification.

 In another aspect thereof, a biomaterial is crosslinked and derivatized with a polyphosphonate:polyepoxide monoadduct. As used herein, the term "derivatized" means that an anticalcification agent, such as the aforementioned a polyphosphonate, is covalently attached to the surface of biomaterial tissue via an epoxy linkage.

15 The term "biomaterial" as used herein refers to collagenous material which may be derived from different animal, typically mammalian, species. The biomaterial is typically suitable for implantation, such as bioprosthetic tissue or the like, but the invention should not be limited thereby. Specific examples include, but are not limited to, heart valves, particularly porcine heart valves; aortic roots, walls,
20 and/or leaflets; bovine pericardium; connective tissue derived materials such as *dura mater*; homograft tissues, such as aortic homografts and saphenous bypass grafts; tendons, ligaments, skin patches, arteries, veins; and the like. Of course, any other biologically-derived materials which are known, or become known, as being suitable for in-dwelling uses in the body of a living being are within the contemplation of the
25 invention.

 Any epoxy compound, which is preferably water-soluble and able to function as a calcium antagonist, is within the contemplation of the invention. Examples of suitable epoxide crosslinking agents, include without limitation, mono- or diepoxides, such as diglycidyl butanediol ester, ethanediol diglycidyl ester, erythritol anhydride

(EDE), butanediol diglycidyl ether (GAB), and epichlorhydrin, as well as polyfunctional epoxides, such as the epoxides sold under the trademark Denacol by Nagasi Chemicals, Osaka, Japan. The Denacol epoxides are polyfunctional polyglycerol polyglycidyl ethers. For example, Denacol 512 has 4 epoxides per molecule and Denacol 521 has 5 epoxides per molecule. As used herein, the term "polyepoxide" means reactive polyfunctional epoxides having at least two epoxy moieties per molecule.

As used herein the term "polyphosphonate" includes compounds having at least two phosphonates per molecule. Such polyphosphonates are commercially available or can be synthesized by those of skill in the art. Exemplary polyphosphonates include 3-amino-1-hydroxypropane 1,1-diphosphonic acid (APD) and ethanehydroxydiphosphonate (EHDP). In certain embodiments, other polyphosphonates, such as aminomethyltriphosphonic acid and butylpentaphosphonic acid are preferred. Additional illustrative examples include, without limitation, hexamethylenediaminetetra(methylenephosphonic acid) and diethylenetriamine-penta(methylenephosphonic acid). However, any anticalcification agent which has at least one functionality of a type which will react with an epoxy functionality is suitable for use in the practice of the invention. Other amino-containing anticalcification agents, such as amino derivatives of phosphocitrate, might be suitable, for example. Additional illustrative examples include, without limitation, hydroxyl, or sulfhydryl derivatives of anticalcification agents.

In one method aspect of the invention, biomaterials are rendered resistant to *in vivo* calcification by subjecting the biomaterial substrate to polyepoxide pretreatment at high pH so as to form irreversible covalent bonds between the polyepoxide and the biomaterial substrate, both crosslinking and blocking calcification sites.

In another method aspect of the invention, calcification-resistant bioprosthetic tissue is prepared by crosslinking, or fixing, the tissue with an epoxide crosslinking agent at physiologic pH, 7.0 - 8.0. A catalytic systems enables polyepoxide crosslinking of bioprosthetic tissue at physiologic pH under aqueous conditions. Aqueous

solutions of polyepoxides incorporating tertiary or quaternary amine catalysts, for example, have been found to produce calcification-resistant tissues.

In still a further method embodiment of the invention, a monoadduct of a polyfunctional anticalcification agent, such as polyphosphonate, and a polyepoxide is formed under conditions where an excess of polyepoxide remains. The excess epoxy crosslinks the tissue and the reactive epoxy functionality of the monoadduct attaches to amino groups of the tissue proteins so as to permanently bind covalently the phosphonate-containing adduct to the tissue.

BRIEF DESCRIPTION OF THE DRAWING

Comprehension of the invention is facilitated by reading the following detailed description, in conjunction with the annexed drawing, in which:

Fig. 1 is a graphical representation of the calcium content ($\mu\text{g}/\text{mg}$) of porcine aortic valve specimens, treated in accordance with methods of the invention, following 21 day subdermal implantation in rats;

Fig. 2 is a graphical representation of the calcium content ($\mu\text{g}/\text{mg}$) of porcine aortic valve specimens, crosslinked with high molecular weight polyepoxides in accordance with methods of the invention, following 21 day subdermal implantation in rats;

Fig. 3 is a graphical representation of the calcium content ($\mu\text{g}/\text{mg}$) of porcine aortic valve specimens exposed to a catalyst;

Fig. 4 is a graphical representation of the calcium content ($\mu\text{g}/\text{mg}$) of porcine aortic valve specimens exposed to epoxide crosslinking agents at high pH levels (10-11) in the presence of another catalyst;

Fig. 5 is a graphical representation of the collagen denaturation temperature ($^{\circ}\text{C}$) for specimens of porcine aortic valves leaflets subjected to epoxide crosslinking agents at pH 10 or 11; and

Fig. 6 is a graphical representation of the collagen denaturation temperature ($^{\circ}\text{C}$) for specimens of porcine aortic valves leaflets subjected to a polyepoxide

crosslinking agent, Denacol, in the presence of a catalyst, at pH levels ranging from 6 to 12.

DETAILED DESCRIPTION OF THE INVENTION

Given below are several specific illustrative techniques for producing calcification-resistant bioprosthetic biomaterials in accordance with the principles of the invention. Although the examples given are primarily directed to the preparation of calcification-resistant heart valve components, the techniques described herein are applicable to the creation of any other device, prosthesis or implant comprising biomaterials of the type used for in-dwelling or surgically implanted devices.

I. Crosslinking Bioprosthetic Tissue With Epoxides

A. High pH Processes

In one method embodiment of the invention, fresh bioprosthetic tissue is incubated in an aqueous solution of a water-soluble epoxide crosslinking agent at a pH of 10 or greater for a time sufficient to permit irreversible cross-linking and blocking of calcification sites. The concentration of the epoxide crosslinking agent, which may be a reactive polyfunctional epoxide or diepoxide, preferably ranges from about 0.01 M to 1.0 M, and more preferably from about 0.05 M to 0.5 M. The solution is buffered to a pH of greater than 10, and preferably in the range of 10 to 11, in any manner known in the art, illustratively with 0.5 M sodium borate.

In preferred embodiments, the incubation time is between about 24 hours and 21 days, typically 7 days. However, the length of time allotted for incubation in the embodiments described hereinabove is illustrative and can be varied by those of skill in the art. It should be noted, however, that no deleterious effects on the bioprosthetic tissue have been observed during the suggested 7 day period. The incubation temperature may range from about 4° C to 63° C, so that proteins in the tissue will not become denatured. Preferably, the temperature is greater than about 20° C, and most preferably in the range of 25° C to 37° C.

Bioprostheses such as porcine aortic valve leaflets or bovine pericardium are typically stabilized and preserved in glutaraldehyde following harvesting,

illustratively in a 0.2% solution of glutaraldehyde in 0.05 HEPES buffer (N-2-hydroxyethylpiperzine-N'-2-ethanesulfonic acid available from Sigma Chemical Co., St. Louis, MO). Glutaraldehyde-preserved bioprostheses can then be stored at 4° C for prolonged periods of time. In accordance with an advantageous embodiment of the invention, glutaraldehyde-pretreated bioprosthetic tissue which is incubated in aqueous solutions of epoxide crosslinking agents in accordance with the principles of the invention exhibit superior calcification resistance.

In a specific illustrative embodiment, porcine aortic valve leaflets are stabilized and preserved in a high pH (> 10, and preferably in the range of 10.5 and 11.5) solution of a low molecular weight epoxide, preferably 4 to 6 carbon atoms in core chain length, such as butanediol diglycidyl ether at 0.1 M, at a temperature of 25° C, for 7 days to confer stability and block calcification sites.

B. Physiological pH Processes

In another method embodiment of the invention, bioprosthetic tissue is exposed to an aqueous solution of a water-soluble epoxide crosslinking agent buffered to physiological pH, *i.e.*, a pH in the range of 7.0 to 8.0, preferably 7.4. The crosslinking solution contains a tertiary or quaternary amine which acts as a "catalyst" to enable polyepoxide crosslinking of bioprosthetic tissue at physiologic pH under aqueous conditions. Suitable tertiary or quaternary amines useful in the practice of the invention, include without limitation, Tris(hydroxymethyl) amino methanehydrochloride (Tris), and imidazole. In some embodiments, the catalyst also buffers the solution.

The epoxide crosslinking agent is present in the aqueous solution in a concentration range of 0.005 M to 0.5 M. The catalyst concentration is typically about 0.01 M, but may be varied relative to the concentration of epoxide crosslinking agent. Other reaction conditions, such as time and temperature, are in accordance with the high pH embodiments described hereinabove.

In a specific illustrative embodiment, a polyepoxide, such as Denacol 521 at 0.1 M concentration is buffered to pH 7.4 with an 0.01 M imidazole or Tris. A bioprosthetic tissue specimen is exposed to the epoxide solution for 7 days at 25° C.

II. Crosslinking and Derivatizing Bioprosthetic Tissue With Polyphosphonate:Polyepoxide Monoadducts

In accordance with an advantageous embodiment of the invention, bioprosthetic tissue can be simultaneously cross-linked and derivatized with a polyphosphonate:polyepoxide monoadduct. Polyphosphonate is combined neat with a stock of pure polyepoxide in a molar ratio of at least a 1:2, and preferably 1:10. Under these conditions, a monoadduct of the polyphosphonate:polyepoxide is preferentially formed, leaving excess unreacted polyepoxide. The monoadduct-containing mixture is diluted with water to a concentration in the range of 0.005 M to 0.5 M, and preferably about 0.1 M. In some embodiments, the monoadduct-containing mixture may be buffered to physiologic pH with the catalytic amines, Tris or imidazole, as described above.

Bioprosthetic tissue, either fresh or glutaraldehyde-pretreated, is exposed to the diluted monoadduct-containing mixture for a time sufficient to both crosslink and reactively bind polyphosphonates to the bioprosthetic tissue. More specifically, the monoadduct-containing mixture, which also contains excess unreacted polyepoxide, crosslinks the tissue with the unreacted polyepoxide while the reactive epoxy functionality of the monoadduct attaches to amino groups of the tissue proteins so as to permanently bind covalently the phosphonate-containing adduct to the tissue. The result is permanent calcification resistance.

In an illustrative embodiment of this aspect of the invention, 1 M APD is added to 10 M of a reactive polyepoxide, such as GAB, and allowed to stand for about 30 minutes to form a monoadduct. The monoadduct solution is diluted with water to 0.1 M concentration and buffered to a pH between 7.5 and 10. Fresh bioprosthetic tissue is exposed to the diluted monoadduct solution for a period of 24 hours to 21 days at a temperature of 25°C to confer crosslinking and derivatization.

It should be noted that the concentration range for the diphosphonate salt (in the pure acid form) is given for purposes of illustration only, and can be varied by those of skill in the art to optimize both binding and cross-linking. Further, the

temperature and length of time allotted for incubation in the embodiments described hereinabove is illustrative and can be varied by those of skill in the art.

Moreover, while an aqueous solution is recommended for bioprosthetic tissue inasmuch as organic solvents have deleterious effects on biologically-based tissue, organic solvents are certainly within the contemplation of the invention. Isopropanol and ethanol, for example, have been used safely in connection with bioprosthetic tissues.

Experimental Section:

Bioprosthetic Tissue in Rat Subdermal Model

Bioprosthetic tissue samples in the form of bovine parietal pericardium from mature cows were obtained at slaughter and immediately placed in solutions of a low molecular weight epoxide, diglycidylbutanediol ester (GAB), and a high molecular weight epoxide, Denacol 521 (DEN), at pH levels of 10 and 11, for 7 days at 37° C. For comparison, some specimens were also incubated in 0.6% glutaraldehyde, at pH 11, for 7 days at 37° C.

The bovine pericardium samples were implanted in two subcutaneous pouches dissected in the ventral abdominal wall of weanling rats (male, CD, Sprague-Dawley, weighing 50-60 gm). After a period of time (21 days and 60 days), the tissue samples were removed and examined for calcification by measuring the level of Ca^{+2} ions in the tissue. The results are reported below in Table I.

TABLE I

Epox.	pH	Phos.	Bound Agent at Implant	Implant (days)	Ca^{2+} ($\mu\text{g}/\text{mg}$)
25	GAB	11	---	21	19.0 $\pm$ 5.9
	GAB	11	---	60	23.4 $\pm$ 10.6
	GAB	10	---	21	61.3 $\pm$ 12.4
	DEN	11	---	60	107.8 $\pm$ 12.7
	GLT	11	---	21	63.5 $\pm$ 7.3
	GLT	11	---	60	109.4 $\pm$ 14.6

30

Notes:

GAB = Diglycidylbutanediol ester

DEN = Denacol 521 (polyglycidyl ether-pentaepoxide)

GLT = Glutaraldehyde

Table I shows significant anticalcification inhibition for specimens of bovine pericardium samples treated in low molecular weight epoxides at high pH.

Bioprosthetic tissue samples in the form of porcine aortic valve leaflets were exposed to solutions of GAB and Denacol 521 at pH levels of 10 and 11, for 7 days at 25° C. Other samples were exposed to monoadduct-containing solutions of APD:GAB and APD:Denacol (1 M polyphosphonate to 10 M polyepoxide) at pH 10 for 7 days at 25° C.

Following exposure to the epoxide crosslinking agents, the leaflet samples were rinsed free of the crosslinking solution and implanted in two subcutaneous pouches dissected in the ventral abdominal wall of weanling rats. After 21 days, the tissue samples were removed and examined for calcification by measuring the level of Ca^{+2} ions in the tissue. The results are shown on Fig. 1 which is a graphic representation of the calcium content, in $\mu\text{g}/\text{mg}$ tissue, for each specimen type. Uncross-linked tissue (fresh) is shown for comparative purposes.

Fig. 2 is a graphical representation of the calcium content ($\mu\text{g}/\text{mg}$) of porcine aortic valve specimens, crosslinked with the high molecular weight polyepoxide, Denacol 521 in accordance with two methods of the invention. In the first method, specimens were exposed to Denacol 521 in an aqueous solution buffered to pH 7.4 with imidazole. In the second method, glutaraldehyde-pretreated specimens were exposed to an aqueous dilution of the monoadduct APD:Denacol 521 (1:10) buffered to pH 7.4 with imidazole. Control specimens are glutaraldehyde cross-linked in accordance with typical practice in the art. For comparative purposes, glutaraldehyde-pretreated specimens were exposed to the diphosphonate, APD, at pH 7.4. As shown in Fig. 2, following 21 days of implantation in rat subdermal pouches, the specimens treated in accordance with the methods of the present invention contained significantly less calcium than the control.

In order to demonstrate that the epoxide crosslinking agent is responsible for the calcification resistance, glutaraldehyde-pretreated porcine aortic valve leaflets were placed in aqueous solutions of imidazole at pH 7.4 and Denacol 521 buffered to pH 7.4 with imidazole at 25° C for 7 days. Glutaraldehyde-pretreated porcine

aortic valve tissue comprises the control. Fig. 3 is a graphical representation of the calcium content ($\mu\text{g}/\text{mg}$) of the specimens explanted at 21 days. The imidazole-catalyzed Denacol solution produced significant reductions in calcium content.

Fig. 4 is a graphical representation of the calcium content ($\mu\text{g}/\text{mg}$) of porcine aortic valve specimens exposed to a low molecular weight epoxide (GAB) and a high molecular weight epoxide (Denacol) at high pH levels (10-11, buffered with NaOH) at 25° C for 7 days in the presence of 0.1 M Tris. The inhibitory effect of Tris catalysis is clearly seen when the results of Fig. 4 are compared to Fig. 1 and Table 1.

Fig. 5 show data demonstrating collagen denaturation temperature or shrink temperature, T_s , equivalent to that derived by using glutaraldehyde for porcine aortic valves leaflets subjected to GAB or Denacol at pH 10 or 11 in accordance with the methods of the invention. The collagen denaturation temperature of fresh, untreated leaflets and glutaraldehyde-treated control leaflets are shown for comparison.

Furthermore, equally satisfactory shrink temperatures can be attained through using epoxide crosslinking agents at physiologic pH through the use of 0.01 M Tris or imidazole. Fig. 6 shows the shrink temperature of porcine aortic valve leaflets exposed for 7 days at 25° C to an aqueous solution of 0.1 M Denacol with 0.01 M imidazole, buffered with NaOH to various pHs ranging from 6 to 12. Glutaraldehyde-treated tissue has a shrink temperature at approximately 87° C.

Although the invention has been described in terms of specific embodiments and applications, persons skilled in the art can, in light of this teaching, generate additional embodiments without exceeding the scope or departing from the spirit of the claimed invention. Accordingly, it is to be understood that the drawing and description in this disclosure are proffered to facilitate comprehension of the invention and should not be construed to limit the scope thereof.

WHAT IS CLAIMED IS:

1. A biologically-derived biomaterial for implantation in the interior of the body of a living being, the biomaterial being substantially insoluble in the interior of the body of a host living being and which has irreversibly bound thereto an effective amount of an epoxide crosslinking reagent to stabilize the biomaterial substrate and block calcification sites thereby rendering said biomaterial substrate resistant to *in vivo* pathologic calcification.

2. The biomaterial of claim 1 wherein the epoxide crosslinking agent is a low molecular weight epoxide selected from the group consisting of diglycidyl butanediol ester, ethanediol diglycidyl ester, butanediol diglycidyl ether, and polyglycerol polyglycidyl ethers of 4 to 6 carbon atoms.

3. The biomaterial of claim 2 wherein the epoxide crosslinking agent is a polyepoxide.

4. The biomaterial of claim 1 or 3 further including a monoadduct of a polyepoxide:polyfunctional anticalcification agent covalently bound to the biologically-derived biomaterial at sites on the biomaterial which are reactive with an epoxy functionality, the anticalcification agent having at least one functional group of a type which will react with an epoxy functionality.

5. The biomaterial of claims 1 or 4 wherein said biologically-derived biomaterial substrate is selected from the group consisting of bovine pericardium, porcine heart valve leaflets, saphenous bypass grafts, aortic homografts, and *dura mater*.

6. A method of treating bioprosthetic tissue comprising incubating the bioprosthetic tissue in a solution of an epoxide crosslinking agent at a pH in excess of 10 for a time sufficient to permit cross-linking of the bioprosthetic tissue.

7. The method of claim 6 wherein the epoxide crosslinking agent is a low molecular weight epoxide selected from the group consisting of diglycidyl butanediol ester, ethanediol diglycidyl ester, butanediol diglycidyl ether, and polyglycerol polyglycidyl ethers of 4 to 6 carbon atoms.

8. The method of claim 6 wherein the time sufficient to permit cross-linking is between about 24 hours and 21 days.

9. A method of treating bioprosthetic tissue comprising incubating the bioprosthetic tissue in a solution of an epoxide crosslinking agent and catalyst at
5 physiologic pH for a time sufficient to permit cross-linking of the bioprosthetic tissue.

10. The method of claim 9 wherein the catalyst is a tertiary or quaternary amine.

11. The method of claim 9 wherein the catalyst is selected from the group
10 consisting of Tris and imidazole.

12. A method of treating bioprosthetic tissue comprising the steps of:

(a) forming a monoadduct of a polyfunctional anticalcification agent and polyepoxide with an excess of polyepoxide;

(b) diluting the monoadduct solution with water; and


15 (c) subjecting bioprosthetic tissue to the diluted aqueous solution of the monoadduct for a time sufficient to crosslink the tissue and to irreversibly derivatize the bioprosthetic tissue with the polyphosphonate anticalcification agent at sites of the biomaterial which are reactive with an epoxy functionality.

13. The method of treating bioprosthetic tissue of claim 12 wherein the
20 polyfunctional anticalcification agent has at least one functional group of a type which will react with an epoxy functionality.

14. The method of treating bioprosthetic tissue of claim 12 wherein the polyfunctional anticalcification agent is a polyphosphonate.

1/6


FIG. 1



SUBSTITUTE SHEET (RULE 26)


2/6

FIG. 2



3/6


FIG. 3



SUBSTITUTE SHEET (RULE 26)


4/6

FIG. 4




5/6

FIG. 5



6/6

FIG. 6



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/13443

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) A61P 2/02

US CL 623/11

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 8/94.11; 600/36; 623/2, 11

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONP

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	US, A, 5,296,583 (LEVY) 22 March 1994, see the entire document.	1-4 ----- 6-9, 12-14
X --- Y	US, A, 5,080,670 (IMAMURA ET AL.) 14 June 1992, see the entire document.	1, 9-11 ----- 2, 3, 6-9, 12-14
Y	US, A, 4,885,005 (NASHEF ET AL.) 05 December 1989, see the entire document.	4, 12-14

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Z" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

16 JANUARY 1996

Date of mailing of the international search report

02 APR 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

Paul Prebilib
PAUL PREBILIC

Telephone No. (703) 308-2905

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/13443

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS

Search Terms: tissue#, polyphosphon?, monoadduct#, diphosphon?, denocol, covalent, epoxide, pericardium, leaflet#, graft, aortic.